Eli Lilly hopes the device can be more convenient for Zepbound users and lead to more people taking the drug.

Eli Lilly announced on " Good Morning America " Monday that its GLP-1 weight-loss drug Zepbound will now be available in a ...

The company said the weight-loss drug will be available at the same self-pay price in either the single-dose vial format or ...

Novo Nordisk’s CagriSema has been outperformed by Eli Lilly’s Zepbound (tirzepatide) in a head-to-head obesity trial. The ...

The CagriSema study results are a setback for the Danish drugmaker in its efforts to regain ground lost to Eli Lilly in the ...

New trial data show tirzepatide outperforms a GLP 1 combo in weight loss, reshaping obesity drug competition, and treatment ...

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a label expansion for Zepbound® (tirzepatide) to include the four-dose single-patient use ...

The failure of its next-generation obesity drug to match Eli Lilly's blockbuster has blown a hole in Novo's post-Ozempic ...

Eli Lilly said on Wednesday the combined use of its weight-loss drug Zepbound with psoriasis treatment Taltz showed better ...

Eli Lilly, the drugmaker behind weight-loss treatments Mounjaro and Zepbound, has rapidly overtaken former market leader Novo ...

Eli Lilly unveiled a new multi-dose version of its blockbuster obesity drug Zepbound, allowing patients to receive a full ...

The FDA has approved a new four-dose, single-patient-use KwikPen for Zepbound (tirzepatide), giving patients a full month of treatment in one device.